Sanofi: Invest Securities optimistic about H2

(CercleFinance.com) - Invest Securities maintains its buy rating on the Sanofi share, pointing out that the second half (H2) will be better.

The broker has set a target price of 85 euros for the share.

According to the broker's analysts, the French pharmaceutical giant's interim results were not particularly surprising, with a continued strong pressure on the Diabetes franchise and MS, a difficult comparison basis for the Vaccines franchise and a recovery in gross margin due to the product mix.

More important is that the broker anticipates that H2 will benefit from the integration of Bioverativ and Ablynx, Vaccines renewing with growth, the rise of Dupixent and Praluent, as well as the approval of Cemiplimab.


Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.